Diverse impact of xeno-free conditions on biological and regenerative properties of hUC-MSCs and their extracellular vesicles
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The therapeutic potential of mesenchymal stem cells (MSCs) not only has been widely studied in animal models [ 1 ] but was also validated for human patients, indicating efficacy in the treatment of a variety of diseases [ 2 , 3 ]. Among different populations of MSCs isolated from various sources, umbilical cord-derived MSC (UC-MSCs) are particularly promising, due to their high proliferative potential, longevity, immunomodulatory properties, and noninvasive isolation procedure [ 4 ]. Interestingly, although the beneficial effects of stem cell-based therapy have been widely appreciated, the level of engrafted cells was usually very low suggesting that the paracrine activity of stem cells rather than direct differentiation plays a key role in tissue repair [ 5 ]. Among paracrine factors, circular cell-membrane enclosed cytoplasmic structures termed extracellular vesicles (EVs) have been recognized as important mediators of cell-to-cell communication [ 6 ]. It was shown that EVs can interact with cell surface receptors or fuse with a cell membrane and transfer bioactive cargo in the form of messenger RNA (mRNA), microRNA (miRNA), proteins, and lipids to the recipient cells, triggering specific intracellular signaling pathways, thereby influencing cell fate [ 6 , 7 ]. Importantly, compelling evidence supports the significance of EV-mediated signaling in a variety of physiological and pathological processes, including embryonic development, the maintenance of tissue homeostasis [ 8 ], spread of pathogens or modulating disease onset, and progression [ 9 ]. Prominently, EVs derived from human mesenchymal stem cells (MCS-EVs) were shown to enhance regeneration of various tissues in animal models [ 10 – 16 ], thus creating a new treatment option for many disorders. In particular, such therapy could be used to improve regeneration of the infarcted or diseased heart, conditions which are the leading causes of morbidity and mortality worldwide [ 17 ], despite the available modalities. To prove this theory, there are reports showing that MSC-EVs infusion to the experimental animals ameliorated myocardial ischemia/reperfusion injury [ 14 ] and markedly enhanced blood flow recovery accompanied by reduction of the infarct size of the heart [ 15 ]. However, to fully translate the beneficial effects of MSC-EVs treatment into the clinic, there is a need to carefully define and standardize cell culture conditions for EVs collection, devoid of any substrates of animal origin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury
Lai, R. C., Arslan, F., Lee, M. M., Sze, N. S. K., Choo, A., Chen, T. S., Salto-Tellez, M., Timmers, L., Lee, C. N., El Oakley, R. M., et al. (2010) · Stem Cell Research · doi:10.1016/j.scr.2009.12.003 · Cited by 2,215
Ratajczak, J., Wysoczynski, M., Hayek, F., Janowska-Wieczorek, A., & Ratajczak, M. Z. (2006) · Leukemia · doi:10.1038/sj.leu.2404296 · Cited by 1,340 · cited 1×
“Importantly, compelling evidence supports the significance of EV-mediated signaling in a variety of physiological and pathological processes, including embryonic development, the maintenance of tissue homeostasis [8], spread of pathogens or modulating disease onset, and progression [9].”
BackgroundLI, X., BAI, J., JI, X., LI, R., XUAN, Y., & WANG, Y. (2014) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2014.1821 · Cited by 301
Oliveira, G. B. F., Avezum, A., & Roever, L. (2015) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2015.00032 · Cited by 109 · cited 1×
“In particular, such therapy could be used to improve regeneration of the infarcted or diseased heart, conditions which are the leading causes of morbidity and mortality worldwide [17], despite the available modalities.”
BackgroundMao, J., Lv, Z., & Zhuang, Y. (2014) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2013.11.005 · Cited by 42 · cited 1×
“cardiomyogenic and cardioprotective role including miR199a-3p, miR-199a-5p [31], and miR-23a-3p [32] in M3- and M4-EVs and elevated level of miR-24a [33] in M3-EVs when compared to the control M6-EVs (Fig.”
Result
Cited by
Harrell, C. R., Jovicic, N., Djonov, V., Arsenijevic, N., & Volarevic, V. (2019) · Cells · doi:10.3390/cells8121605 · Cited by 795
The Pros and Cons of Mesenchymal Stem Cell-Based Therapies
Musiał-Wysocka, A., Kot, M., & Majka, M. (2019) · Cell Transplantation · doi:10.1177/0963689719837897 · Cited by 534
Mesenchymal Stem Cells for Neurological Disorders
Andrzejewska, A., Dabrowska, S., Lukomska, B., & Janowski, M. (2021) · Advanced Science · doi:10.1002/advs.202002944 · Cited by 359
Adamiak, M., Cheng, G., Bobis-Wozowicz, S., Zhao, L., Kedracka-Krok, S., Samanta, A., Karnas, E., Xuan, Y.-T., Skupien-Rabian, B., Chen, X., et al. (2018) · Circulation Research · doi:10.1161/circresaha.117.311769 · Cited by 335
Self-citationLiu, S., Mahairaki, V., Bai, H., Ding, Z., Li, J., Witwer, K. W., & Cheng, L. (2019) · Stem Cells · doi:10.1002/stem.2996 · Cited by 164
Metadata
- Authors
- Bobis-Wozowicz, S., Kmiotek, K., Kania, K., Karnas, E., Labedz-Maslowska, A., Sekula, M., Kedracka-Krok, S., Kolcz, J., Boruczkowski, D., Madeja, Z., & Zuba-Surma, E. K.
- Venue
- Journal of Molecular Medicine
- Published
- 2016-09-16
- Volume
- 95
- Issue
- 2
- Pages
- 205-220
- ISSN
- 0946-2716 (ISSN-L)
- 1432-1440
- OpenAlex
- W2519374566
- Cited by
- 81
- References
- 5
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.